Metabolomics study of esophageal adenocarcinoma

Jian Zhang, Lingyan Liu, Siwei Wei, G. A. Nagana Gowda, Zane Hammoud, Kenneth Kesler, Daniel Raftery

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Objective: The objective of this study was to detect and evaluate reliable metabolite markers for screening and monitoring treatment of patients with esophageal adenocarcinoma (EAC) by studying metabolomics. The sensitivity and specificity of the study were evaluated not only for EAC but also for Barrett esophagus and high-grade dysplasia, which are widely regarded as precursors of EAC. Methods: Profiles of metabolites in blood serum were constructed using nuclear magnetic resonance spectroscopy and statistical analysis methods. The metabolite biomarkers discovered were selected to build a predictive model that was then used to test the classifications accuracies. Results: Eight metabolites showed significant differences in their levels in patients with cancer and in the control group on the basis of Student t test. A partial least-squares discriminant analysis model built on these metabolites provided excellent classifications of patients with cancer and the control group, with the area under the receiver operating in a characteristic curve of > 0.85 for both training and validation sample sets. Evaluated by the same model, the Barrett esophagus samples were of mixed classification, and the high-grade dysplasia samples were classified primarily as cancer samples. A pathway study indicated that altered energy metabolism and changes in the trochloroacetic acid cycle were the dominant factors in the biochemistry of EAC. Conclusions: 1H nuclear magnetic resonance-based metabolite profiling analysis was shown to be an effective approach to differentiating between patients with EAC and healthy subjects. Good sensitivity and selectivity were shown by using the 8 metabolite markers discovered to predict the classification of samples from the healthy control group and the patients with the disease. Serum metabolic profiling may have potential for early diagnosis of EAC and may enhance our understanding of its mechanisms.

Original languageEnglish
Pages (from-to)469-475
Number of pages7
JournalJournal of Thoracic and Cardiovascular Surgery
Volume141
Issue number2
DOIs
StatePublished - Feb 2011

Fingerprint

Metabolomics
Adenocarcinoma
Barrett Esophagus
Control Groups
Magnetic Resonance Spectroscopy
Neoplasms
Physiologic Monitoring
Discriminant Analysis
Least-Squares Analysis
Serum
Biochemistry
Energy Metabolism
Early Diagnosis
Healthy Volunteers
Biomarkers
Students
Sensitivity and Specificity
Acids

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Zhang, J., Liu, L., Wei, S., Nagana Gowda, G. A., Hammoud, Z., Kesler, K., & Raftery, D. (2011). Metabolomics study of esophageal adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery, 141(2), 469-475. https://doi.org/10.1016/j.jtcvs.2010.08.025

Metabolomics study of esophageal adenocarcinoma. / Zhang, Jian; Liu, Lingyan; Wei, Siwei; Nagana Gowda, G. A.; Hammoud, Zane; Kesler, Kenneth; Raftery, Daniel.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 141, No. 2, 02.2011, p. 469-475.

Research output: Contribution to journalArticle

Zhang, J, Liu, L, Wei, S, Nagana Gowda, GA, Hammoud, Z, Kesler, K & Raftery, D 2011, 'Metabolomics study of esophageal adenocarcinoma', Journal of Thoracic and Cardiovascular Surgery, vol. 141, no. 2, pp. 469-475. https://doi.org/10.1016/j.jtcvs.2010.08.025
Zhang, Jian ; Liu, Lingyan ; Wei, Siwei ; Nagana Gowda, G. A. ; Hammoud, Zane ; Kesler, Kenneth ; Raftery, Daniel. / Metabolomics study of esophageal adenocarcinoma. In: Journal of Thoracic and Cardiovascular Surgery. 2011 ; Vol. 141, No. 2. pp. 469-475.
@article{dd572f17f691458da2aa5c4e508b7629,
title = "Metabolomics study of esophageal adenocarcinoma",
abstract = "Objective: The objective of this study was to detect and evaluate reliable metabolite markers for screening and monitoring treatment of patients with esophageal adenocarcinoma (EAC) by studying metabolomics. The sensitivity and specificity of the study were evaluated not only for EAC but also for Barrett esophagus and high-grade dysplasia, which are widely regarded as precursors of EAC. Methods: Profiles of metabolites in blood serum were constructed using nuclear magnetic resonance spectroscopy and statistical analysis methods. The metabolite biomarkers discovered were selected to build a predictive model that was then used to test the classifications accuracies. Results: Eight metabolites showed significant differences in their levels in patients with cancer and in the control group on the basis of Student t test. A partial least-squares discriminant analysis model built on these metabolites provided excellent classifications of patients with cancer and the control group, with the area under the receiver operating in a characteristic curve of > 0.85 for both training and validation sample sets. Evaluated by the same model, the Barrett esophagus samples were of mixed classification, and the high-grade dysplasia samples were classified primarily as cancer samples. A pathway study indicated that altered energy metabolism and changes in the trochloroacetic acid cycle were the dominant factors in the biochemistry of EAC. Conclusions: 1H nuclear magnetic resonance-based metabolite profiling analysis was shown to be an effective approach to differentiating between patients with EAC and healthy subjects. Good sensitivity and selectivity were shown by using the 8 metabolite markers discovered to predict the classification of samples from the healthy control group and the patients with the disease. Serum metabolic profiling may have potential for early diagnosis of EAC and may enhance our understanding of its mechanisms.",
author = "Jian Zhang and Lingyan Liu and Siwei Wei and {Nagana Gowda}, {G. A.} and Zane Hammoud and Kenneth Kesler and Daniel Raftery",
year = "2011",
month = "2",
doi = "10.1016/j.jtcvs.2010.08.025",
language = "English",
volume = "141",
pages = "469--475",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Metabolomics study of esophageal adenocarcinoma

AU - Zhang, Jian

AU - Liu, Lingyan

AU - Wei, Siwei

AU - Nagana Gowda, G. A.

AU - Hammoud, Zane

AU - Kesler, Kenneth

AU - Raftery, Daniel

PY - 2011/2

Y1 - 2011/2

N2 - Objective: The objective of this study was to detect and evaluate reliable metabolite markers for screening and monitoring treatment of patients with esophageal adenocarcinoma (EAC) by studying metabolomics. The sensitivity and specificity of the study were evaluated not only for EAC but also for Barrett esophagus and high-grade dysplasia, which are widely regarded as precursors of EAC. Methods: Profiles of metabolites in blood serum were constructed using nuclear magnetic resonance spectroscopy and statistical analysis methods. The metabolite biomarkers discovered were selected to build a predictive model that was then used to test the classifications accuracies. Results: Eight metabolites showed significant differences in their levels in patients with cancer and in the control group on the basis of Student t test. A partial least-squares discriminant analysis model built on these metabolites provided excellent classifications of patients with cancer and the control group, with the area under the receiver operating in a characteristic curve of > 0.85 for both training and validation sample sets. Evaluated by the same model, the Barrett esophagus samples were of mixed classification, and the high-grade dysplasia samples were classified primarily as cancer samples. A pathway study indicated that altered energy metabolism and changes in the trochloroacetic acid cycle were the dominant factors in the biochemistry of EAC. Conclusions: 1H nuclear magnetic resonance-based metabolite profiling analysis was shown to be an effective approach to differentiating between patients with EAC and healthy subjects. Good sensitivity and selectivity were shown by using the 8 metabolite markers discovered to predict the classification of samples from the healthy control group and the patients with the disease. Serum metabolic profiling may have potential for early diagnosis of EAC and may enhance our understanding of its mechanisms.

AB - Objective: The objective of this study was to detect and evaluate reliable metabolite markers for screening and monitoring treatment of patients with esophageal adenocarcinoma (EAC) by studying metabolomics. The sensitivity and specificity of the study were evaluated not only for EAC but also for Barrett esophagus and high-grade dysplasia, which are widely regarded as precursors of EAC. Methods: Profiles of metabolites in blood serum were constructed using nuclear magnetic resonance spectroscopy and statistical analysis methods. The metabolite biomarkers discovered were selected to build a predictive model that was then used to test the classifications accuracies. Results: Eight metabolites showed significant differences in their levels in patients with cancer and in the control group on the basis of Student t test. A partial least-squares discriminant analysis model built on these metabolites provided excellent classifications of patients with cancer and the control group, with the area under the receiver operating in a characteristic curve of > 0.85 for both training and validation sample sets. Evaluated by the same model, the Barrett esophagus samples were of mixed classification, and the high-grade dysplasia samples were classified primarily as cancer samples. A pathway study indicated that altered energy metabolism and changes in the trochloroacetic acid cycle were the dominant factors in the biochemistry of EAC. Conclusions: 1H nuclear magnetic resonance-based metabolite profiling analysis was shown to be an effective approach to differentiating between patients with EAC and healthy subjects. Good sensitivity and selectivity were shown by using the 8 metabolite markers discovered to predict the classification of samples from the healthy control group and the patients with the disease. Serum metabolic profiling may have potential for early diagnosis of EAC and may enhance our understanding of its mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=78751579001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751579001&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2010.08.025

DO - 10.1016/j.jtcvs.2010.08.025

M3 - Article

C2 - 20880550

AN - SCOPUS:78751579001

VL - 141

SP - 469

EP - 475

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 2

ER -